Dowiedzieć się o najlepszych cenach i klinikach w chemioterapii w Hiszpanii w 2025 roku

Dr Agusti Barnadas Molins jest znanym specjalistą w dziedzinie onkologii medycznej, który koncentruje się na leczeniu raka piersi. Ma ponad 35 lat doświadczenia, a jego praktyki obejmują chemioterapię, terapię gruczołową raka piersi i immunoterapię raka piersi. Pełnił funkcję głównego badacza w ponad 70 projektach badawczych i jest autorem lub współautorem ponad 130 oryginalnych artykułów. Zajmował prestiżowe stanowiska, takie jak prezes Catalan-Balearyjskiego Towarzystwa Onkologicznego i sekretarz generalny Hiszpańskiego Towarzystwa Onkologii Medycznej (SEOM).

Dr. Lana Bijelic is a board-certified oncological surgeon. She specializes in peritoneal carcinomatosis. Since 2019, she has been part of the Carcinomatosis Surgical Group at the Teknon Oncology Institute. She trained under Prof. Paul Sugarbaker at Washington Hospital Center and brings strong expertise to her team.

Dr. Bijelic has worked as Research Director at Inova Fairfax Hospital. She has also been an associate professor at Virginia Commonwealth University and Georgetown University. She is an active member of the American College of Surgeons and the Society of Surgical Oncology.

Throughout her career, Dr. Bijelic has received many academic awards, including several Surgical Excellence Awards and top prizes in research. She is known for her leadership and important contributions to surgical oncology.

Dr. Jesus Soberino is an oncologist at Vall d’Hebron University Hospital and the Vall d’Hebron Institute of Oncology (VHIO). He specializes in breast cancer and melanoma. Dr. Soberino has led many phase 1–3 clinical trials. His work has helped approve important drugs, including CDK4/6 inhibitors for metastatic breast cancer and immunotherapies for melanoma.

His areas of expertise include endocrine therapy, managing hormone resistance, and developing new immunotherapies. Dr. Soberino is known for his patient-centered care. He actively collaborates in research to improve cancer treatment. He is accredited by VHIO and is a key member of the Breast Cancer and Melanoma Units.

Dr. Francesc Graus is a neurologist with expertise in paraneoplastic neurological syndromes, gliomas, and primary brain lymphomas. He established the first strict diagnostic criteria for paraneoplastic syndromes. He also identified important antibodies that are now used in diagnosis. His research showed the link between tumors and autoimmune neurological attacks.

Dr. Graus earned his MD and PhD from Universitat Autònoma de Barcelona. He completed his neurology residency in Barcelona and a neuro-oncology fellowship at Memorial Sloan-Kettering Cancer Center. He is an Emeritus investigator at IDIBAPS. He founded and served as president of the European Association of Neuro-Oncology. He is also the former chief of neurology at Hospital Clinic Barcelona.